[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cystitis-recurrent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cystitis-recurrent":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100585809","phase-1-daily-nitrofurantoin-versus-bladder-fulguration-plus-daily-nitrofurantoin-for-women-with-recurrent-urinary-tract-infections-100585809",false,"NCT06907199","Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for Women With Recurrent Urinary Tract Infections","A Multicentric Randomized Trial of Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for the Long-term Management of Cystitis in Women With Recurrent Urinary Tract Infections","Inclusion Criteria:\n\n* Females 18 to 85 years old with at least a 1-year history of culture documented uncomplicated rUTI.\n* Diagnosis of rUTI, defined as ≥ 3 symptomatic UTIs in 12 months or ≥ 2 in 6 months.\n* Currently free from a UTI determined based on absence of symptoms as determined by the UTI symptom assessment questionnaire and negative urine culture (\\\u003C10\\^3 colony forming units per ml of urine).\n* A negative upper and lower urinary tract evaluation, including pelvic examination for pelvic organ prolapse (less than or equal to stage 2), measurement of post-void residual (less than 50 ml), and imaging (which may include renal ultrasound and standing voiding cystourethrogram) to exclude kidney stone, hydronephrosis, reflux, or urethral diverticulum.\n* Office cystoscopy documenting stages 1 or 2 of chronic cystitis.\n* Likely to stay in the geographic region for the duration of the study.\n* ASA class II or less.\n\nExclusion Criteria:\n\n* Patients on antibiotics at baseline (i.e., suppressive therapy or antibiotic therapy for non-urinary infections).\n* Patients on self-start therapy (i.e., taking antibiotics upon start of urinary symptoms concerning for UTI).\n* Patients on prophylactic antibiotics started in the last 3 months and unwilling to discontinue, or intention to start in the next 12 months.\n* Complicated UTIs, including neurogenic bladder condition (i.e., multiple sclerosis, Parkinson's disease, spinal cord injury), bladder augmentation, or urinary diversion.\n* Patients with urinary catheters (including indwelling Foley, intermittent catheterization, and suprapubic catheters).\n* Uncontrolled diabetes (HbA1c \\>9).\n* Pregnancy\n* Allergy or resistance to Nitrofurantoin.\n* Chronic lung or liver condition precluding the use of Nitrofurantoin, including abnormal chest X ray or elevated liver function tests.\n* Chronic renal insufficiency (creatinine over 1.5 g\u002Fdl or GFR less than 40) precluding the use of Nitrofurantoin.\n* History of chronic diarrhea requiring regular therapy.\n* Patients with psychosis, dementia, swallowing disorders, or any other ability to take Nitrofurantoin reliably at home.\n* BMI over 40.\n* Use of Uromune or other vaccine approaches to reduce rUTI episodes\n* Participation in a research study involving an investigational product in the past 12 weeks.\n* Patients receiving phage therapy.\n* Current diagnosis of interstitial cystitis.\n* Patients with medical conditions requiring excessively large amounts of fluid intake.","FEMALE","18 Years","85 Years",{"count":20,"type":21},104,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goal of this clinical trial is to learn if the drug Nitrofurantoin (NF) taken as a daily antibiotic, works to treat cystitis compared to electrofulguration (EF) and Nitrofurantoin (NF) daily antibiotic.",[27,28],"Recurrent UTIs","Cystitis Recurrent",[30,31,32,33,34],"bladder fulguration","Nitrofurantoin","long-term managenent of cystitis","Recurrent UTI","chronic UTI","RECRUITING","2026-04-27",{"date":38,"type":39},"2026-05-01","ACTUAL",{"date":41,"type":39},"2026-04-06",{"date":43,"type":21},"2029-01-30",{"name":45,"class":46},"University of Texas Southwestern Medical Center","OTHER",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100607277","phase-4-microbiome-modulating-prophylaxis-rct-antibiotic-vs-gynoflor-in-postmenopausal-women-with-recurrent-cystitis-100607277","NCT07186465","Microbiome-Modulating Prophylaxis RCT: Antibiotic vs Gynoflor in Postmenopausal Women With Recurrent Cystitis","Evaluating Urinary Microbiome Modulation :An RCT of Antibiotic vs Gynoflor Prophylaxis in Postmenopausal Women With Recurrent Cystitis","microbiome","Inclusion Criteria:\n\n* Female, postmenopausal, age ≥40 years\n* Clinical history of recurrent urinary tract infection (rUTI) as assessed by the investigator\n* Able and willing to take assigned prophylaxis for 6 months\n* Able to attend baseline and Month 6 study visits and provide urine samples\n* Able to provide written informed consent\n* Willing and able to complete twice-weekly phone\u002FLINE follow-ups\n\nExclusion Criteria:\n\n* Current symptomatic UTI at enrollment (may be treated and reconsidered after resolution)\n* Known hypersensitivity or contraindication to nitrofurantoin or to the Lactobacillus\u002Festriol vaginal tablet (Gynoflor) or their excipients; significant renal impairment or other label-based contraindications to nitrofurantoin per local practice\n* Planned urologic surgery or procedure expected during the 6-month study period\n* Recent bacterial vaginosis (e.g., within the past month) or active vulvovaginal skin disorders precluding vaginal product use\n* History of hormone-dependent malignancy (e.g., breast, uterine, or cervical cancer) or unexplained abnormal vaginal bleeding\n* Significant liver disease (e.g., active hepatitis) or other conditions judged by the investigator to make participation unsafe\n* Participation in another interventional trial that could interfere with outcomes\n* Withdrawal of consent or severe adverse event requiring discontinuation","40 Years",{"count":58,"type":21},100,[60],"PHASE4","This open-label, parallel-group randomized controlled trial compares two prophylaxis strategies for recurrent urinary tract infection (rUTI) in postmenopausal women: (1) nightly oral nitrofurantoin 100 mg for 6 months versus (2) a vaginal tablet containing Lactobacillus with ultra-low-dose estriol (Gynoflor: nightly for 14 days, then twice weekly to month 6). Participants (≥40 years) are randomized 1:1 in computer-generated blocks and followed for 6 months. The primary endpoint is the proportion with rUTI recurrence within 6 months. Secondary endpoints include time to first recurrence, antibiotic resistance in breakthrough infections, change in lower urinary tract symptoms (Thai RUTISS), and urinary microbiome measures (Lactobacillus dominance and community diversity by qPCR and 16S rRNA). Key assessments occur at baseline and month 6 (urinalysis, culture, urinary microbiome sampling, and kidney function). Adherence and adverse events are captured via twice-weekly phone\u002FLine contacts. Approximately 100 participants (50 per arm) will be enrolled as a feasibility-sized pilot.",[63,64],"Cystitis, Recurrent","Urinary Tract Infections",[66,31,67,68,69,70,71,72,73,74,75,76,77,78,79],"Postmenopausal Women","Antibiotic Prophylaxis","Gynoflor","Lactobacillus","Estriol","Vaginal Probiotics","Urinary Microbiome","16S rRNA Sequencing","qPCR","Lower Urinary Tract Symptoms","RUTISS Questionnaire","Adherence Monitoring","Antimicrobial Resistance","Thailand","2025-09-22",{"date":82,"type":39},"2025-09-25",{"date":84,"type":39},"2025-09-11",{"date":86,"type":21},"2026-08-30",{"name":88,"class":46},"Mahidol University",1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":18,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":103,"conditions":104,"keywords":112,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":89},"100588378","a-trial-of-d-mannose-for-the-prophylaxis-of-recurrent-urinary-tract-infections-100588378","NCT06940622","A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections","A Randomized Controlled Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections in Post-menopausal Women","DmannoseRCT","Inclusion Criteria:\n\n* Female, post-menopausal, age ≥ 55 years old\n* Diagnosis of recurrent UTI, defined as ≥ 3 symptomatic culture-proven UTI episodes in 12 months or ≥ 2 in 6 months.\n* Currently free from a UTI determined based on absence of symptoms as determined by the UTI symptom assessment questionnaire79 and negative urine culture (\\\u003C103 colony forming units per ml of urine).\n* Able to attend all follow-up appointments for the study.\n* A negative upper and lower urinary tract evaluation, including pelvic examination for pelvic organ prolapse (less than stage 2), measurement of post-void residual (less than 50 ml), and imaging (renal ultrasound and standing voiding cystourethrogram) to exclude kidney stone, hydronephrosis, reflux, or urethral diverticulum.\n\nExclusion Criteria:\n\n* Current use of D-mannose. Patients willing to stop taking D-mannose will be offered to join the trial after a 4-week wash-out period.\n* Complicated UTIs, including need for catheter drainage or intermittent catheterization, neurogenic bladder, bladder augmentation, or urinary diversion.\n* Ongoing supplement use (Box 1). Patients willing to stop taking the listed supplements will be offered to join the trial after a 4-week wash-out period.\n* Evidence of upper tract infection (pyelonephritis), including temperature higher than 38°C, flank\u002Flumbar pain or tenderness\n* Diagnosis of interstitial cystitis or overactive bladder syndrome\n* Prophylactic antibiotics started in the last 3 months and unwilling to discontinue, or intention to start in the next 12 months\n* Use of Uromune or other vaccine approaches to reduce rUTI\n* Participation in a research study involving an investigational product in the past 12 weeks\n* Receipt of phage treatment\n* History of chronic diarrhea requiring regular therapy\n* Inability to swallow or known history of gastrointestinal malabsorption\n* History of recurrent vaginal yeast infections\n* Systemic disease precluding enrollment in this study (uncontrolled diabetes with HgA1C above 7, ongoing chemotherapy or immunotherapy, renal insufficiency \\[creatinine \\> 1.5 g\u002Fdl\\]), mental or cognitive impairment, weight loss diet requiring excessively large amounts of fluid intake, or other health-related specific diet).\n* Nursing home resident\n* BMI \\>40\n\nBox 1 Supplements to avoid\n\n* Multi-Vitamins and Multi-Mineral capsules\n* Specific Vitamins or Minerals (e.g., Calcium, Citrical, Calcium Gummies, Vitamin A, D, Niacin, Pyridoxine, Selenium, Vitamin E, B6, Iron, Omega 3, D3, Magnesium, B-Complex, Women's Ultra MultiVitamin, GNC B-Complex, B-12, PreserVision Areds2, Vitamins D, B Pollen)\n* Probiotics\n* Cranberry Mannose or Cranberry Extract Weight loss products to avoid\n* Medifast\n* Vitafusion\n* OptiVin Products\n* Appetite Suppressants\n* Keto-Fuel","55 Years",{"count":100,"type":21},90,[102],"NA","A randomized, double-blind, placebo-controlled, 12-month study to determine the effectiveness of D-mannose (2g daily) supplementation in rUTI (recurrent urinary tract infection) prevention in post-menopausal women.",[27,105,106,107,28,108,109,110,111],"Recurrent Urinary Tract Infections","Recurrent Urinary Tract Infections in Women","Recurrent Urinary Tract Infection","Cystitis Chronic","UTI","UTI - Urinary Tract Infection","UTI - Lower Urinary Tract Infection",[113,114,115,116,117,118,119,120,121],"D-mannose","dmannose","uti","ruti","recurrent urinary tract infection","urinary tract infection","cystitis","chronic uti","chronic cystitis","2025-09-18",{"date":80,"type":39},{"date":125,"type":39},"2025-08-01",{"date":127,"type":21},"2030-09-30",{"name":45,"class":46}]